Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors

Patent metadata

Field	Value
Publication number	US-9643967-B2
Application number	US-201415103900-A
Country	US
Kind code	B2
Filing date	Dec 12, 2014
Priority date	Dec 13, 2013
Publication date	May 9, 2017
Grant date	May 9, 2017

Abstract

The present invention provides a heterocyclic compound having a TLR7, TLR9, TLR7/8, TLR7/9 or TLR7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

First claim

The invention claimed is:

1. A compound represented by the formula (I):

wherein
R 1 is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an optionally substituted hydroxy group, an optionally substituted amino group, an optionally substituted sulfanyl group, or an acyl group,
R 2 , R 3 and R 4 are independently a hydrogen atom or a substituent selected from the group consisting of a halogen atom, a cyano group, a nitro group, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an optionally substituted hydroxy group, an optionally substituted amino group, an optionally substituted sulfanyl group, and an acyl group,
Ring A is an optionally substituted ring,
Ring B is an optionally substituted heterocycle,
Ring C is an optionally substituted 3- to 10-membered nitrogen-containing heterocycle,
L 1 is a bond or a divalent hydrocarbon group,
L 2 is a bond, —O—, —C(O)—, —NH—C(O)—, —C(O)—NH—, —S—, —SO—, —SO 2 —, —SO 2 —O—, —O—SO 2 — or —CH(CN)—,
L 3 is a bond or a divalent hydrocarbon group, with the proviso that at least one of L 1 , L 2 and L 3 is not a bond, and
L 4 is a bond or a spacer having 1 to 6 atoms,
or a salt thereof.

2. The compound or salt of claim 1 , wherein
R 1 is a hydrogen atom, a C 1-10 alkyl group or a C 3-10 cycloalkyl group,
R 2 is a hydrogen atom or a C 1-10 alkyl group,
R 3 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted hydroxy group,
R 4 is a hydrogen atom, a halogen atom or an optionally substituted hydrocarbon group,
Ring A is an optionally substituted C 3-10 cycloalkane, an optionally substituted C 3-10 cycloalkene, an optionally substituted C 6-14 aromatic hydrocarbon or an optionally substituted aromatic heterocycle optionally fused with benzene,
Ring B is an optionally substituted 3- to 10-membered non-aromatic heterocycle,
Ring C is an optionally substituted 5- or 6-membered nitrogen-containing aromatic heterocycle or an optionally substituted 3- to 10-membered nitrogen-containing non-aromatic heterocycle,
L 1 and L 3 are independently
(1) a bond,
(2) a C 1-10 alkylene group, or
(3) a C 3-8 cycloalkylene group,
L 2 is a bond or —C(O)—, and
L 4 is a bond, a straight chain C 1-6 alkylene group, —X 1 —O—X 2 —, —X 1 —C(O)—X 2 — or —X 1 —NH—C(O)—X 2 —, wherein X 1 and X 2 are independently a bond or a straight chain C 1-5 alkylene group, and the total atom number is 6 or less.

3. The compound or salt of claim 1 , which is 4-[2-[4-[4-(4-isopropylpiperazin-1-yl)phenyl]-6,7-dimethyl-1H-pyrrolo[3,2-c]pyridin-2-yl]ethyl]morpholine or a salt thereof.

4. The compound or salt of claim 1 , which is 4-[2-[4-[4-(4-isopropylpiperazin-1-yl)phenyl]-1,6-dimethyl-pyrrolo[3,2-c]pyridin-2-yl]ethyl]morpholine or a salt thereof.

5. The compound or salt of claim 1 , which is 4-[[4-[4-(4-isopropylpiperazin-1-yl)phenyl]-1H-pyrrolo[3,2-c]pyridin-2-yl]methyl]morpholine or a salt thereof.

6. The compound or salt of claim 1 , which is 4-[4-(4-isopropylpiperazin-1-yl)phenyl]-2-(1-piperidylmethyl)-1H-pyrrolo[3,2-c]pyridine or a salt thereof.

7. A pharmaceutical composition comprising the compound or salt of claim 1 .

8. The pharmaceutical composition of claim 7 , which is a TLR7, TLR9, TLR7/8, TLR7/9 or TLR7/8/9 inhibitor.

9. The pharmaceutical composition of claim 7 , which is an agent for the treatment of an autoimmune disease and/or an inflammatory disease, wherein the autoimmune disease and/or inflammatory disease is selected from the group consisting of systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis and inflammatory bowel disease.

10. A method of inhibiting TLR7, TLR9, TLR7/8, TLR7/9 or TLR7/8/9 in a mammal, which comprises administering an effective amount of the compound or salt of claim 1 to the mammal.

11. A method for the treatment of an autoimmune disease and/or an inflammatory disease in a mammal, wherein the autoimmune disease and/or inflammatory disease is selected from the group consisting of systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis and inflammatory bowel disease, which comprises administering an effective amount of the compound or salt of claim 1 to the mammal.

Assignees

• Takeda Pharmaceuticals Co

Inventors

• Koul Summon
• Kurhade Suresh
• Bhosale Sandeep
• Naik Keshav
• Salunkhe Videsh
• Munot Yogesh
• Bhuniya Debnath

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title